Giant cell arteritis, polymyalgia rheumatica, ANCA-associated vasculitides
Conditions
Interventions
Group 1: Self-management group: digital questionnaires, independent blood sampling, urine measurements, photo/video documentation every 4 weeks, on-site appointments as part of routine care every 3-6
Sponsors
Rheumazentrum Ruhrgebiet, Universitätsklinikum der Ruhr-Universität Bochum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Diagnosis of vasculitis/PMR (ICD-10: M30.1, M31.1, M31.7, M31.5, M31.4, M35.3, M35.3) - Consent of the patient - Patient capable of giving consent
Exclusion criteria
Exclusion criteria: - Failure to meet the inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of flares confirmed by rheumatologists between routine appointments | — |
Secondary
| Measure | Time frame |
|---|---|
| - Change in disease damage (VDI - vasculitis damage index) from baseline to end of study - Difference in patient satisfaction at the end of the study? (eZAP, TUUSQ) Exploratory endpoints: - Time (days) from baseline to the first disease activity-driven intensification (escalation) of therapy for the underlying disease - Molecular and cellular biomarkers and cell-cell interactions in the pathogenesis of the disease, with a particular focus on the occurrence of relapses - Differences in the use of medical resources - Rate of disease activity-driven intensification of therapy (escalation) for the underlying disease - Total number of infections requiring antibiotics - Use of medical resources (consultations, outpatient/inpatient appointments) - Adjustment of antidiabetic therapy (newly started/dose increased) - Adjustment of antihypertensive therapy (newly started/dose increased) - Change in cortisone dose from baseline to end of study - Adherence to home monitoring | — |
Countries
Germany
Contacts
Public ContactAnna Kernder
Rheumazentrum Ruhrgebiet, Universitätsklinikum der Ruhr-Universität Bochum
Outcome results
None listed